Class Action Cases

United Therapeutics Corporation

Join Class Action »

On February 21, 2018, United Therapeutics disclosed that its cost of product sales was above expectations due to an increase in the royalty rate United Therapeutics is required to pay Eli Lilly for Adcirca under an amended licensed agreement. On this news, shares of United Therapeutics fell $17.41 or approximately 12.9% over the next two trading days to close at $117.55 per share on February 22, 2018.

Press Release

Coming soon.